XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib

Reem Ali(Hamad bin Khalifa University), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Adel Alblihy(University of Nottingham), Mashael Algethami(University of Nottingham), Rabab Al Sunni(University of Nottingham), Andrew R. Green(Nottingham Biomedical Research Centre), Michael S. Toss(Nottingham City Hospital)
Therapeutic Advances in Medical Oncology
January 1, 2020
10.1177/1758835920974201
Cited by 26

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374